Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1

Conditions

Neoplasms 2Small Cell Lung Carcinoma 1Leukemia, Myeloid, Acute 1Leukemia 1Carcinoma, Small Cell 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × GSK2879552 × Clear all
NCT02034123 2019-12-06

Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma

GlaxoSmithKline

Phase 1 Terminated
29 enrolled 34 charts
Thoracic

Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

NCT02177812 2019-06-28

A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML)

GlaxoSmithKline

Phase 1 Terminated
41 enrolled 34 charts
Other hematologic neoplasm

Leukemia, Neoplasms, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡